

S 3702

Right Rebate Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Dec 4, 2018

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Dec 4, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/3702>

Sponsor

Name: Sen. Wyden, Ron [D-OR]

Party: Democratic • **State:** OR • **Chamber:** Senate

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Grassley, Chuck [R-IA]	R · IA		Dec 4, 2018
Sen. Blumenthal, Richard [D-CT]	D · CT		Dec 6, 2018
Sen. Brown, Sherrod [D-OH]	D · OH		Dec 6, 2018
Sen. Cortez Masto, Catherine [D-NV]	D · NV		Dec 6, 2018
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Dec 6, 2018
Sen. Klobuchar, Amy [D-MN]	D · MN		Dec 10, 2018
Sen. Stabenow, Debbie [D-MI]	D · MI		Dec 10, 2018
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Dec 12, 2018
Sen. Ernst, Joni [R-IA]	R · IA		Dec 13, 2018
Sen. Smith, Tina [D-MN]	D · MN		Dec 17, 2018

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Dec 4, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 7223	Identical bill	Dec 13, 2018: Referred to the Subcommittee on Health.
115 HR 7217	Related bill	Dec 12, 2018: Received in the Senate.

Right Rebate Act of 2018

This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

Actions Timeline

- **Dec 4, 2018:** Introduced in Senate
- **Dec 4, 2018:** Read twice and referred to the Committee on Finance.